Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Despite treatment with anti-HIV drugs, people infected with HIV continue to have problems with their immune systems. This study will evaluate whether the drug thalidomide, which stimulates the immune system's T cells, can improve immune system function in people with HIV.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Thalidomide

Criteria

Inclusion Criteria

• HIV-infected for at least 5 years prior to study entry

• CD4 count of 300/mm3 or above

• Pre-HAART nadir CD4 count of 300/mm3 or less

• CMV infection

• HAART for 12 months prior to study entry

• Same effective HAART regimen for 3 months prior to study entry

• HIV viral load less than 200 copies/ml

• Clinically stable

Exclusion Criteria

• Active opportunistic infection

• Females of childbearing potential